Ariad Pharmaceuticals Inc (ARIA): Hugh M Cole , SVP, Chief Business Officer of Ariad Pharmaceuticals Inc sold 6,012 shares on Jun 28, 2016. The Insider selling transaction was reported by the company on Jun 29, 2016 to the Securities and Exchange Commission. The shares were sold at $7.05 per share for a total value of $42,384.60 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 23, 2016, Timothy P Clackson (President, R&D, CSO) sold 23,999 shares at $7.28 per share price.On Jun 15, 2016, Athanese Lavidas (director) sold 76,250 shares at $8.20 per share price.Also, On Jun 14, 2016, Massimo Radaelli (director) sold 108,569 shares at $8.23 per share price.On May 13, 2016, Paris Panayiotopoulos (CEO) purchased 26,990 shares at $7.41 per share price.
Shares of Ariad Pharmaceuticals (ARIA) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.44 points or -6.13% at $6.74 with 46,25,188 shares getting traded. Post opening the session at $7.1, the shares hit an intraday low of $6.7 and an intraday high of $7.19 and the price vacillated in this range throughout the day. The company has a market cap of $1,289 M and the number of outstanding shares has been calculated to be 19,12,31,460 shares. The 52-week high of Ariad Pharmaceuticals is $10.07 and the 52-week low is $4.37.
Company has been under the radar of several Street Analysts.Ariad Pharmaceuticals is Reiterated by Barclays to Underweight and the brokerage firm has raised the Price Target to $ 8 from a previous price target of $6 .The Rating was issued on May 11, 2016.
ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).